14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
KTTA vs CLYM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (43.7/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 5–1 (led by Balance Sheet & Cash Flow), while KTTA wins 2–1 across the 6-pillar growth and valuation breakdown. KTTA trades at $0.48 (N/M Forward P/E, 0.0% operating margin) versus CLYM at $9.19 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. KTTA 42.1/100 HOLD) and 1.42β · 106% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KTTA vs CLYM. Trailing 12-month operating profitability (KTTA 0.0% vs CLYM 0.0%) and valuation multiples (KTTA N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $545.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KTTA vs CLYM Key Questions & Quantitative Answers
As of Nov 20, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (43.7/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 5–1 (led by Balance Sheet & Cash Flow), while KTTA wins 2–1 across the 6-pillar growth and valuation breakdown. KTTA trades at $0.48 (N/M Forward P/E, 0.0% operating margin) versus CLYM at $9.19 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. KTTA 42.1/100 HOLD) and 1.42β · 106% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KTTA leads the Growth & Scale pillar: KTTA posts +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, KTTA generates $486,559 in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, KTTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.
KTTA screens cheaper on headline valuation multiples. KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KTTA (-88.8% ROE) versus CLYM (-29.3% ROE) capital efficiency.
In options market volatility and institutional positioning, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 106% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.